Reuters: IPOX® Associate Lukas Muehlbauer Comments on Cerebras’ IPO and AI Chip Demand

Reuters reported that Cerebras Systems is targeting a valuation of up to $26.62 billion in its U.S. IPO, as demand for AI chips and infrastructure continues to support investor interest in the sector. The Nvidia rival plans to sell 28 million shares priced between $115 and $125 each, aiming to raise $3.50 billion in its renewed attempt to go public.

IPOX® Associate Lukas Muehlbauer was quoted throughout the article, providing context on Cerebras’ positioning in the AI infrastructure market and the broader significance of the transaction for IPO investors. His comments addressed both Cerebras’ competitive pitch against Nvidia and the role of the listing as a signal deal for the IPO market.

The article also highlighted improving IPO market conditions, with AI and financials expected to remain key areas of investor focus. Muehlbauer noted that Cerebras’ listing could help test public investor demand for high-growth AI infrastructure companies, particularly ahead of other large anticipated listings.

“Nvidia remains dominant as the market leader for AI inference as well as training infrastructure, however, Cerebras is pitching the idea that there is room for specialist chip companies if they can offer clear speed or cost advantages,” IPOX® Research Associate Lukas Muehlbauer said.

“Cerebras is an important signal deal for the IPO market as a test of whether public investors are ready to fund high-growth AI infrastructure companies after a softer start to the year,” Muehlbauer said.

“There is also a race to get deals done before SpaceX. The SpaceX IPO will be so large and high-profile that there are concerns it could absorb a lot of investor attention and capital.”

Read the full article by Echo Wang, Manya Saini and Pritam Biswas on Reuters: Cerebras targets $26.6 billion valuation in US IPO as AI chip demand surges

Previous
Previous

Reuters: IPOX® CEO Josef Schuster Comments on Blackstone Data Center Vehicle’s U.S. IPO

Next
Next

The IPOX® Update 5/2/2026